Kairos Pharma has shared interim safety data from its ongoing Phase I clinical trial evaluating ENV-105 (carotuximab) in combination with osimertinib (AstraZeneca’s Tagrisso) in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). The company says the data represent a pivotal milestone in its lead programme: resensitising patients… Read More
Neil Bhowmick, Chief Scientific Officer at Kairos Pharma, explores the biology of cancer drug resistance and the opportunities to overcome it. Despite extraordinary advancements in how we treat cancer, ranging from cytotoxic chemotherapy to precision immunotherapies, one fundamental barrier consistently impedes… Read More
Kairos Pharma has entered into binding terms to acquire CL-273, an investigational, reversible, wild-type-sparing pan‑EGFR small‑molecule inhibitor, from Celyn Therapeutics. CL-273 was discovered using a proprietary AI-driven drug discovery platform. It targets the resistant mutations that develop when using EGFR tyrosine kinase inhibitors,… Read More
